Galapagos NV (Euronext & NASDAQ: GLPG) and NovAliX have joined forces in a strategic collaboration, aiming to accelerate innovation, reduce risks, and shorten drug development timelines.
Galapagos’ research and discovery capabilities and dedicated employees based in Romainville, France, will be transferred to NovAliX, a drug discovery-focused Contract Research Organization.
This collaboration follows Galapagos’ renewed focus on its key therapeutic areas of oncology and immunology, as the company moves to become a fit-for-purpose research and development (R&D) organization.
NovAliX and Galapagos have recently announced an exciting agreement that will see the transfer of Galapagos’ drug discovery and research activities conducted in Romainville, France to NovAliX. In exchange, Galapagos will benefit from the research capabilities and expertise of NovAliX through a five-year collaboration.
The financial impact is included in Galapagos’ 2023 cash burn guidance, and the transaction is expected to close in July 2023. This exciting move brings together two innovative players in the field of drug discovery and research, and promises to yield many exciting results.
Galapagos is thrilled to announce that we have come to an agreement with NovAliX, in order to continue our Forward, Faster strategy, and to ensure the continued employment of our colleagues at our research site in Romainville.
Our teams and NovAliX have worked closely together for the past several months to make this agreement possible, and we have complete faith that our transferred colleagues, alongside the teams at NovAliX, will bring great success in the future. Paul Stoffels, CEO and Chairman of Galapagos, expresses his gratitude for the trust and commitment demonstrated by everyone involved.
NovAliX is thrilled to announce its integrated drug discovery collaboration with Galapagos. With the acquisition of Galapagos’ drug discovery and research activities in Romainville, along with its highly skilled team, NovAliX will now have access to a full range of drug discovery capabilities and innovative technologies in kidney diseases, fibrosis and immunology.
This addition to NovAliX’s existing expertise in oncology and infectious diseases is a huge step forward in its growth strategy, highlighting the emergence of new partnership models between CROs and the biopharmaceutical industry. We look forward to a long and fruitful partnership with Galapagos and the teams that will be joining us.
At Galapagos, we strive to make a difference in the lives of patients worldwide by developing innovative medicines to treat diseases with unmet needs.
Our research and development capabilities span multiple drug modalities, including small molecules and cell therapies, and our portfolio ranges from discovery to commercialized programs in immunology, oncology, and more. Our first medicine for rheumatoid arthritis and ulcerative colitis is now available in Europe and Japan, and we are committed to continuing to bring groundbreaking treatments to those in need.
NovAliX is a pioneering drug discovery CRO that offers a comprehensive suite of services to support therapeutic programs, from target identification to preclinical candidate delivery.
Our award-winning team of medicinal chemistry and pharmacology scientists, together with a variety of screening and characterization technologies, including a robust DNA-encoded library platform and a comprehensive portfolio of biophysical techniques, including an in-house cryo-EM facility, is at the forefront of drug discovery in key therapeutic areas such as oncology, inflammation, fibrosis, and infectious and kidney diseases.